drugset / Trial / NCT05238441
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
RandomizedParallel-groupTriple-blindPrevention
Summary
The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.
Timeline
- Start
- 2022-03-20
- Primary completion
- 2022-06-01
- Completion
- 2023-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | SCTV01E | Vaccine | — | Intramuscular |